Tollen v. Geron Corporation

Opinion

1 2 3 4 5 6 UNITED STATES DISTRICT COURT 7 NORTHERN DISTRICT OF CALIFORNIA 8

10 MICHAEL TOLLEN, on behalf of himself and a class of similarly situated investors, 11 No. C 20-00547 WHA Plaintiff, 12 Related to v. 13 No. C 20-01163 WHA GERON CORPORATION and JOHN A. 14 SCARLETT, ORDER (1) CONSOLIDATING 15 Defendants. ACTIONS; (2) APPOINTING LEAD

16 PLAINTIFF; AND (3) INVITING APPLICATIONS FOR LEAD 17 COUNSEL EUGENE CONNOR, on behalf of himself 18 and a class of similarly situated investors, 19 Plaintiff, 20 v.

21 GERON CORPORATION and JOHN A. SCARLETT, 22 Defendants. 23

24 INTRODUCTION 25 Pursuant to the Private Securities Litigation Reform Act, this order APPOINTS Julia and 26 Richard Junge as lead plaintiffs. This order accordingly DENIES the motions of other parties 27 1 for appointment as lead plaintiff. This order also GRANTS the motion to consolidate cases and 2 sets forth the procedure to be used for the selection and approval of class counsel. 3 STATEMENT 4 On January 23, 2020, individual investor Michael Tollen filed a putative securities action 5 against defendant Geron Corporation and individual defendant John Scarlett, the President and 6 CEO of Geron, alleging false and misleading statements in violation of federal securities laws. 7 That same day, Tollen’s counsel published a notice on PRNewswire informing investors that a 8 class action lawsuit had been filed against Geron and that investors had 60 days from the 9 publication of the notice to seek appointment as lead plaintiff. A second such class action was 10 filed in this district by individual Eugene Connor on February 14, 2020, and was later related 11 by this Court. 12 Plaintiff alleges Geron misled investors regarding a drug called imetelstat and its 13 corresponding clinical study, IMbark. Geron allegedly chose to cite certain positive metrics 14 regarding the studies of the drug during an investor call and in its financial statements that 15 caused its stock price to increase, as opposed to citing primary endpoint data or other less 16 positive metrics that would have helped investors evaluate the true viability of the drug. When 17 Geron finally announced the drug’s failure and the corresponding data, its stock price dropped. 18 Eight lead plaintiff candidates timely filed motions for appointment: (1) Tak Wing Yuen, 19 (2) Timothy Willison and Thomas Cooper, (3) Patricia Markham, (4) Kevin Courtney, (5) Dr. 20 Robert Ham, (6) Trevor Conti (7) Julia Junge and Richard Junge, and (8) Stuart Gaumer. 21 Patricia Markham, Trevor Conti, Stuart Gaumer, Kevin Courtney, and Timothy Willison and 22 Thomas Cooper have all withdrawn their motions. Tak Wing Yuen has filed a statement of 23 non-opposition. Thus, Dr. Robert Ham as well as Julia and Richard Junge remain. 24 The undersigned requested that each lead plaintiff candidate file responses to a 25 questionnaire about his or her qualifications, experience in managing litigation, transactions in 26 the shares at issue, and any potential conflicts related to the instant securities litigation. Dr. 27 Ham and the Junges have submitted answers to the lead plaintiff questionnaire. A telephonic 1 Ham were questioned on their qualifications. Following the hearing on the same day, an order 2 requested additional information from the movants. In response, the Junges filed two 3 handwritten questionnaires and a joint declaration. Dr. Ham filed an opposition to the Junges’ 4 filing. 5 ANALYSIS 6 1. CONSOLIDATION. 7 Under FRCP 42(a), the district court may consolidate actions where the actions involve a 8 “common question of law or fact.” The “district court has broad discretion under this rule to 9 consolidate cases pending in the same district.” Investors Research Co. v. U.S. Dist. Court for 10 Cent. Dist. of Cal., 877 F.2d 777, 777 (9th Cir. 1989). The complaints do not need to be 11 identical for purposes of consolidation. 12 Here, both complaints allege claims under Section 10(b), 20(a) of the 1934 Exchange Act 13 as well as Rule 10b-5, and include allegations regarding Geron’s announcements of certain 14 metrics regarding imetelstat and IMbark. The complaints also share the same class period. 15 Because the complaints involve common questions of fact and law, the motion to consolidate 16 is GRANTED. 17 2. APPOINTMENT OF LEAD PLAINTIFF. 18 Under the PSLRA, the district court “shall appoint as lead plaintiff the member or 19 members of the purported plaintiff class that the court determines to be most capable of 20 adequately representing the interests of the class members . . . in accordance with this 21 subparagraph.” 15 U.S.C. § 78u-4(a)(3)(B)(i); 15 U.S.C. § 77z-1(a)(3)(B)(i). The PSLRA 22 creates a rebuttable presumption that the most adequate plaintiff should be the plaintiff who: 23 (1) has filed the complaint or brought the motion for appointment of lead counsel in response 24 to the publication of notice; (2) has the “largest financial interest” in the relief sought by the 25 class; and (3) otherwise satisfies the requirements of FRCP 23. 15 U.S.C. § 78u- 26 4(a)(3)(B)(iii)(I)(aa)–(cc); 15 U.S.C. § 77z-1(a)(3)(B)(iii)(I)(aa)–(cc). The above presumption 27 may be rebutted only upon proof that the presumptive lead plaintiff: (1) will not fairly and 1 such plaintiff incapable of adequately representing the class. 15 U.S.C. § 78u- 2 4(a)(3)(B)(iii)(II)(aa)–(bb); 15 U.S.C. § 77z-1(a)(3)(B)(iii)(II)(aa)–(bb). 3 The PSLRA establishes a three-step inquiry for appointing a lead plaintiff. First, a 4 plaintiff files the action and posts notice, allowing other lead plaintiff candidates to file 5 motions. Second, the district court considers which of those plaintiffs has the largest financial 6 interest in the action and whether that plaintiff meets the requirements of FRCP 23. Third, 7 other candidates have the opportunity to rebut the presumption that the putative lead plaintiff 8 can adequately represent the class and to compete themselves for the job. In re Cavanaugh, 9 306 F.3d 726, 729–30 (9th Cir. 2002). 10 A. LARGEST FINANCIAL INTEREST. 11 The PSLRA does not indicate a specific method for calculating which plaintiff has the 12 “largest financial interest.” See 15 U.S.C. § 78u-4(a)(3)(B)(iii)(I)(bb). Our court of appeals 13 also has not prescribed a particular method for calculating a plaintiff’s financial interest but has 14 directed that “the court may select accounting methods that are both rational and consistently 15 applied.” In re Cavanaugh, 306 F.3d at 730 n.4. 16 Here, the movants calculate financial interest based on the losses suffered. Under this 17 test, courts consider: “(1) the number of shares purchased during the class period; (2) the 18 number of net shares purchased during the class period; (3) the total net funds expended during 19 the class period; and (4) the approximate losses suffered during the class period.” In re 20 Diamond Foods, Inc., Sec. Litig., 281 F.R.D. 405, 408 (N.D. Cal. 2012). The fourth factor, the 21 net “approximate loss,” is generally considered the most important factor. Absent proof that 22 the lead plaintiff candidate with the largest financial interest does not satisfy the requirements 23 of FRCP 23, said candidate is “entitled to lead plaintiff status.” In re Cavanaugh, 306 F.3d at 24 732. 25 The Junges purchased 148,336 shares during the class period and suffered an estimated 26 net loss of $457,253.74 calculated under both LIFO and FIFO. Dr. Ham purchased 405,403 27 shares during the class period and suffered an estimated net loss of $282,994.39 calculated 1 financial interest within the meaning of the statute, they are presumptively the most adequate 2 lead plaintiff. 3 B. REQUIREMENTS OF TYPICALITY AND ADEQUACY UNDER RULE 23. 4 Once a court determines which plaintiff has the largest financial interest, “the court must 5 appoint that plaintiff as lead, unless it finds that [plaintiff] does not satisfy the typicality or 6 adequacy requirements.” In re Cavanaugh, 306 F.3d at 732. 7 The typicality requirement is satisfied when the putative lead plaintiff has suffered the 8 same injuries as absent class members as a result of the same conduct by the defendants. 9 Hanon v. Dataproducts Corp., 976 F.2d 497, 508 (9th Cir. 1992). In the instant action, the 10 alleged announcement of certain imetelstat and IMbark metrics during the class period and the 11 drug’s subsequent failure caused the Junges as well as Dr. Ham and absent class members alike 12 to suffer financial loss. As a result, the Junges claims are based on the same legal theories as 13 other class members. Dr. Ham’s claims are also based on the same legal theories as the other 14 class members. 15 The adequacy requirement of FRCP 23(a)(4) permits certification only if “the 16 representative parties will fairly and adequately protect the interests of the class.” The two key 17 inquiries are (1) whether there are conflicts within the class; and (2) whether plaintiff a counsel 18 will vigorously fulfill their duties to the class. Ellis v. Costco Wholesale Corp., 657 F.3d 970, 19 985 (9th Cir. 2011). In its response to the lead plaintiff questionnaire, the Junges state that 20 they have never been lead plaintiff in a case nor do they have any experience with litigation. 21 They are, however, willing to travel as needed to carry out the lead plaintiff responsibilities. 22 Similarly, Dr. Ham has never been lead plaintiff in a case and does not have litigation 23 experience. He, too, asserts that there are no time or travel impediments to carrying out his 24 responsibilities as lead plaintiff in this action. 25 C. ATTEMPTS TO REBUT PRESUMPTION. 26 Dr. Ham opposes the appointment of the Junges as lead plaintiff on three grounds. First, 27 he argues that the Junges have failed to make a prima facie evidentiary showing of their 1 adequacy. Specifically, although their counsel submitted a declaration, the Junges themselves 2 did not initially submit a declaration regarding their background or adequacy to serve as lead 3 plaintiff or setting forth facts concerning their relationship with each other. Second, Dr. Ham 4 argues that without a declaration, the Junges are inadequate because they may be “two investors 5 with no decision-making structure.” Third, Dr. Ham notes a number of deficiencies in the Junges’ 6 response to the Court’s questionnaire that make them an inadequate lead plaintiff. 7 In support of his arguments, Dr. Ham has cited to cases from other district courts that 8 have denied applications for appointment as lead plaintiff on the ground that the lead plaintiff 9 candidate did not, for example, provide evidence of his competency or basic details about 10 himself. See, e.g., Camp v. Qualcomm Inc., 2019 WL 277360, at *3 (S.D. Cal. Jan. 22, 2019); 11 In re Gemstar-TV Guide Int’l, Inc. Sec. Litig., 209 F.R.D. 447, 452 (C.D. Cal. 2002). 12 Initially, the Junges only submitted a declaration from counsel, not one signed by 13 themselves. They have now submitted a joint signed declaration in response to the April 30 14 order. The declaration includes, among other things, detailed information about their 15 educational background, employment, and their investment in Geron. Thus, unlike the lead 16 plaintiff candidates in the above-mentioned cases who provided little to no information about 17 themselves, the Junges have provided sufficient background information, thereby addressing 18 this concern as to their adequacy as lead plaintiff. 19 Dr. Ham also argues that the Junges have failed to make a prima facie showing of their 20 adequacy because they did not initially submit a signed declaration. Dr. Ham further contends 21 that any subsequent declarations submitted are inadequate under 15 U.S.C. § 78u-4(a)(3). The 22 PSLRA sections Dr. Ham cites to require a lead plaintiff candidate to move the court to serve 23 as lead plaintiff within 60 days of notice publication. Here, even though the Junges’ timely 24 motion was not accompanied by their signed declaration, the new declaration submitted in 25 response to the April 30 order is sufficient at this stage to make a prima facie showing as to 26 their adequacy. There is no case law stating that a signed supplemental response submitted 27 after the 60-day period delineated by the PSLRA belies the legitimacy or timeliness of the 1 concern that the Junges failed to initially submit their owned signed declaration with their 2 motion and did not do so until the Court provided a second chance. 3 As to Dr. Ham’s second concern, it is true we tend to be skeptical about “artificial” 4 groups even though more than one person can be appointed as lead plaintiff. In re Network 5 Assocs., Inc., Sec. Litig., 76 F. Supp. 2d 1017, 1027 (N.D. Cal. 1999). The issue with 6 appointing a disparate, unrelated group is that it would encourage lawyers to direct the litigation, as 7 opposed to allowing plaintiffs to seek out the lawyers as the PSLRA intended. See H.R. Conf 8 Rep. No. 104–369, at 35 (1995). In this case, however, in their motion and declaration, the 9 Junges explained their relationship as husband and wife. They are not unrelated investors 10 without a connection other than counsel. 11 As to his third concern, Dr. Ham points to a number of shortcomings with the Junges’ 12 questionnaire response. In particular, Dr. Ham notes that the original questionnaire submitted 13 by the Junges was not written in Julia or Richard’s own handwriting as directed by the Court 14 and that the response was prepared with assistance of counsel. One of the purposes of the 15 PSLRA is to prevent lawyer-driven litigation, and to ensure that the lead plaintiff is the one 16 who actively manages the litigation on behalf of the class, not counsel. The original 17 shortcomings pointed out by Dr. Ham ⁠— a typewritten questionnaire response and reliance on 18 counsel ⁠— do cast some doubt on whether the Junges understood that lawyers should not be 19 directing this litigation. The Junges have now, however, submitted new handwritten responses 20 to the questionnaire. Their joint declaration also states that they understand “the lead plaintiff 21 shall have the authority and responsibility to manage the case and to direct lead counsel.” 22 Combined with the statements made by the Junges and the directions given during the April 30 23 hearing, the Court is satisfied that the Junges understand what their duties would be in 24 managing the litigation as lead plaintiff, and the importance of preventing lawyer-controlled 25 litigation in this matter. 26 Dr. Ham also notes that the initial questionnaire response did not address how the Junges 27 would manage the litigation with Richard in Texas and Julia in Alaska for part of the year on a 1 also did not address counsel’s agreement with the Junges that it would advance all reasonable 2 costs and expenses in this litigation, even if there is no recovery. Based on the Junges’ updated 3 declaration noting their “long-standing cooperation and joint decision-making as a married 4 couple” as well as further questioning by the Court of their ability to manage the litigation at 5 the April 30 hearing, this order finds the Junges have satisfied the requirements of typicality 6 and adequacy. Accordingly, Julia Junge and Richard Junge are hereby APPOINTED as lead 7 plaintiff. 8 The Court appreciates Dr. Ham’s assistance in evaluating the Junges. Dr. Ham may be 9 correct that the Junges are mere puppets of their lawyers. If this pattern persists, we will 10 reevaluate their suitability as lead plaintiff. In the meantime, the Court reminds the Junges that 11 they must, on their own, interview and select counsel who will do the best job for the class, 12 taking into account all the required factors, including capping his fee request. Further details 13 regarding selecting counsel are below. 14 INSTRUCTIONS TO JULIA AND RICHARD JUNGE 15 Julia and Richard Junge are hereby appointed lead plaintiff. The following sets forth the 16 procedure for selecting and approving class counsel. Under the PSLRA, “[t]he most adequate 17 plaintiff shall, subject to the approval of the court, select and retain counsel to represent the 18 class.” 15 U.S.C. § 78u-4(a)(3)(B)(v). Selection and approval require an assessment of the 19 strengths, weaknesses, and experience of counsel as well as the financial burden — in terms of 20 fees and costs — on the class. Wenderhold v. Cylink Corp., 191 F.R.D. 600, 602–03 (N.D. 21 Cal. February 4, 2000) (Judge Vaughn R. Walker). 22 Any important decision made by a fiduciary should be preceded by due diligence. A lead 23 plaintiff is a fiduciary for the investor class. No decision by the lead plaintiff is more 24 important than the selection of class counsel. Consequently, the lead plaintiff should precede 25 its choice with due diligence. The extent of such due diligence is a matter of judgment and 26 reasonableness based on the facts and circumstances. 27 The lead plaintiff may consider its current counsel along with all other candidates but it 1 candidate’s fee proposal, its track record, the particular lawyers to be assigned to the case, the 2 candidate’s ability and willingness to finance the case, the candidate’s proposals for the 3 prosecution of the case, and the factors set forth in the questionnaire. 4 The lead plaintiff should immediately proceed to perform its due diligence in the 5 selection of class counsel, and to interview appropriate candidates. Counsel wishing to apply 6 to be considered for the role of lead counsel should promptly contact Julia and Richard Junge 7 at: g 18102 Talavera Ridge, Apt. 2401 San Antonio, TX 78257 9 Telephone: (405) 317-6580 Email: jjunge@ ymail.com 10 Julia and Richard Junge shall promptly advertise for applicants and leave open the M application period for class counsel until JUNE 5, 2020, and shall make a final decision as to 12 the selection of counsel by JUNE 19, 2020. Both Junges must interview and evaluate all

,O = 13 candidates. Through counsel, Julia and Richard Junge shall move for the appointment and

approval of their selected counsel no later than JULY 9, 2020. The motion should be

2 15 accompanied by a declaration from the lead plaintiff explaining the due diligence undertaken

A 16 with respect to the selection of class counsel. The declaration should also explain why the

= M7 counsel selected was favored over other potential candidates. The declaration should be filed

18 under seal and not served on defendants. The motion for approval of lead plaintiffs choice of 19 counsel, however, should be served on defense counsel. No hearing will be held on the motion 20 unless the Court determines that it would be beneficial. 21 22 IT IS SO ORDERED. 23 4 1 Dated: May 14, 2020. 25 26 |! ( 4 / + | foe □ 27 LIAM ALSUP UNITED STATES DISTRICT JUDGE 28